O impacto que a suplementação de micronutrientes e alterações dietéticas tem na migrânea
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Analisar os principais artigos disponíveis sobre o impacto que a suplementação de micronutrientes e alterações dietéticas tem nos pacientes com migrânea. Revisão bibliográfica: A migrânea é uma doença neurológica crônica cuja fisiopatologia ainda não está totalmente esclarecida, embora saiba-se da presença de citocinas inflamatórias e dos desequilíbrios iônicos. Como um tratamento alternativo ou complementar ao tradicional, a suplementação de magnésio, isoflavonas de soja, nano-curcumina, ômega 3 isolado ou em associação com a nano-curcumina, zinco, ácido lipóico e vitamina D foram benéficos aos pacientes com enxaqueca. Além disso, mudanças dietéticas que aumentem o consumo de ácidos graxos n-3 e diminuam os n-6 e a dieta cetogênica também tiveram resultados favoráveis na frequência e duração das crises de migrânea. Considerações finais: A enxaqueca é uma doença neurológica amplamente disseminada em nível global, com uma fisiopatologia e um tratamento complexos. Vários fatores podem influenciar a sua manifestação, e intervenções como a suplementação de micronutrientes e mudanças na dieta podem ser eficazes para melhorar a perspectiva e a qualidade de vida dos pacientes, sem causar efeitos colaterais. Portanto, é essencial que os profissionais da saúde avaliem individualmente cada paciente com enxaqueca, a fim de proporcionar um tratamento eficaz e um prognóstico favorável.
##plugins.themes.bootstrap3.article.details##
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
2. AHMADI H, et al. Zinc supplementation affects favorably the frequency of migraine attacks: a double-blind randomized placebo-controlled clinical trial. Nutrition Journal. 2020;19 (1).
3. AKBARI M, et al. The effects of alpha-lipoic acid supplementation on inflammatory markers among patients with metabolic syndrome and related disorders: a systematic review and meta-analysis of randomized controlled trials. Nutrition & Metabolism. 2018; 15 (1).
4. ALTUNKAYNAK Y, et al. Serum lactic acid and pyruvic acid levels in patients with migraine and tension type headache. Dusunen Adam: The Journal of Psychiatry and Neurological Sciences. 2013; 276–80.
5. ATTERITANO M, et al. Genistein effects on quality of life and depression symptoms in osteopenic postmenopausal women: a 2-year randomized, double-blind, controlled study. Osteoporosis International. 2013; 25(3):1123–9.
6. BABAPOUR M, et al. Effect of soy isoflavones supplementation on migraine characteristics, mental status and calcitonin gene-related peptide (CGRP) levels in women with migraine: results of randomised controlled trial. Nutrition Journal. 2022; 21(1).
7. BOSKA MD, et al. Contrasts in cortical magnesium, phospholipid and energy metabolism between migraine syndromes. Neurology. 2002; 58(8):1227–33.
8. CAPRIO M, et al. Very-low-calorie ketogenic diet vs hypocaloric balanced diet in the prevention of high-frequency episodic migraine: the EMIKETO randomized, controlled trial. Journal of Translational Medicine. 2023; 21(1).
9. CEGIELSKA J, et al. Migraine and Its Association with Hyperactivity of Cell Membranes in the Course of Latent Magnesium Deficiency—Preliminary Study of the Importance of the Latent Tetany Presence in the Migraine Pathogenesis. Nutrients. 2021; 13(8):2701.
10. CHEN D. Analysis of omega-3 and omega-6 polyunsaturated fatty acid metabolism by compound-specific isotope analysis in humans. Jorunal of lipid research. 2023.
11. Di LORENZO C, et al. A Randomized Double-Blind, Cross-Over Trial of very Low-Calorie Diet in Overweight Migraine Patients: A Possible Role for Ketones? Nutrients. 2019; 11(8):1742.
12. GHORBANi Z, et al. The effects of vitamin D supplementation on interictal serum levels of calcitonin gene-related peptide (CGRP) in episodic migraine patients: post hoc analysis of a randomized double-blind placebo-controlled trial. The Journal of Headache and Pain. 2020; 21(1).
13. GHORBANI Z, et al. Vitamin D in migraine headache: a comprehensive review on literature. Neurological Sciences: Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2019; 40(12):2459–77.
14. GONULLU H, et al. The levels of trace elements and heavy metals in patients with acute migraine headache. JPMA The Journal of the Pakistan Medical Association. 2015; 65(7):694–7.
15. GROSS EC, et al. Defining metabolic migraine with a distinct subgroup of patients with suboptimal inflammatory and metabolic markers. Scientific Reports. 2023; 13(1).
16. GROSS EC, et al. Mitochondrial function and oxidative stress markers in higher-frequency episodic migraine. Scientific Reports. 2021; 11(1):4543.
17. IKEDA A, et al. Resolvin D1 suppresses inflammation-induced hyperexcitability of nociceptive trigeminal neurons associated with mechanical hyperalgesia. Brain Research Bulletin. 2020 Jan 1; 154:61–7.
18. JAROSZ M, et al. Antioxidant and anti-inflammatory effects of zinc. Zinc-dependent NF-κB signaling. Inflammopharmacology. 2017; 25(1):11–24.
19. KELISHADI MR, et al. The beneficial effect of Alpha-lipoic acid supplementation as a potential adjunct treatment in episodic migraines. Scientific Reports. 2022; 12(1).
20. LI H, et al. Leukocyte inflammatory phenotype and function in migraine patients compared with matched non-migraine volunteers: a pilot study. BMC neurology. 2022; 22(1).
21. MACINTOSH B. Methodology for altering omega-3 EPA+DHA and omega-6 linoleic acid as controlled variables in a dietary trial. Clinical Nutrition. 2021.
22. MAYANS L, WALLING A. Acute Migraine Headache: Treatment Strategies. American Family Physician. 2018; 97(4):243–51.
23. MEßLINGER K. Bedeutung des, calcitonin gene-related peptide“ (CGRP) in der Pathophysiologie von Migräne und Clusterkopfschmerz. Der Schmerz. 2020; 34(2):181–7.
24. OLESEN J. Understanding the Biologic Basis of Migraine. New England Journal of Medicine. 1994; 331(25):1713–4.
25. RAMSDEN CE, et al. Dietary alteration of n-3 and n-6 fatty acids for headache reduction in adults with migraine: randomized controlled trial. BMJ. 2021; 374:n1448.
26. RAMSDEN CE, et al. Targeted alteration of dietary n-3 and n-6 fatty acids for the treatment of chronic headaches: A randomized trial. Pain. 2013; 154(11):2441–51.
27. SAN MAURO MARTIN I, et al. Effects of Gluten on Gut Microbiota in Patients with Gastrointestinal Disorders, Migraine, and Dermatitis. Nutrients. 2024; 16(8):1228.
28. SEDIGHIYAN M, et al. The effects of nano-curcumin supplementation on adipokines levels in obese and overweight patients with migraine: a double blind clinical trial study. BMC Research Notes. 2022;15(1).
29. VINOGRADOVA LV. Initiation of spreading depression by synaptic and network hyperactivity: Insights into trigger mechanisms of migraine aura. Cephalalgia. 2017; 38(6):1177–87.
30. WANG HF, et al. A 12-week randomized double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine. Brain, Behavior, and Immunity. 2024;118:459–67.
31. ZIS P, et al. Headache Associated with Coeliac Disease: A Systematic Review and Meta-Analysis. Nutrients. 2018; 10(10):1445.